Following up here with speculative estimates of the rate of spread of Omicron and a stab at how to apportion this rapid rate of spread between intrinsic transmissibility and immune escape. 1/18
Monday's post was mainly meant to emphasize that observed rapid spread of Omicron can be influenced by both intrinsic transmissibility and immune escape. Here, I'll try to put (speculative) numbers on this rate of spread. 2/18
Key datapoints include rapid displacement of existing Delta viruses by Omicron in Gauteng and South Africa. Estimates of logistic growth rate here by @TWenseleers imply Omicron has ~5X current transmission rate of Delta. 3/18
But as stated previously, I believe this estimate is likely to drop somewhat as more data comes in. But I wouldn't be surprised if this drops to something still significant, say 3X or 4X the transmission rate of Delta in South Africa. 4/18
In addition to changes in relative frequency, we can look at what's happening with case counts, which have been rising rapidly in Gauteng and South Africa. We can measure the exponential growth in cases via Rt (the number of secondary cases caused by an index case). 5/18
In work from @lrossouw we get a rapid rise in Rt in Gauteng from ~0.8 to ~2.5 over the course of Nov corresponding to the take off of Omicron (unsupervised.online/static/covid-1…). 6/18
Work from @seabbs and colleagues gives a similar result of Rt increasing from ~0.8 to above 2 over the course of November in Gauteng (epiforecasts.io/covid/posts/su…). 7/18
I've revised my own phylodynamic estimates of rate of spread with a couple improvements. First off, I'm now using 206 Omicron genomes generously shared by researchers through @GISAID. 8/18
Secondly, I'm now masking spike which has issues of spurious within-Omicron diversity due to amplicon dropout during sequencing. I've adjusted molecular clock rate from 8×10^-4 to 5.5×10^-4 to compensate (determined from sequences taken over the course of the pandemic). 9/18
This updated analysis gives a median estimate of the common ancestor to Omicron viruses of Sep 30 with a 95% credible interval of between Sep 9 and Oct 13. 10/18
This also gives a median estimate of doubling time of 4.9 days, which we can convert to an estimate of Rt assuming a generation interval of 5.1 days (eurosurveillance.org/content/10.280…). Doing so gives a median estimate of Rt of 2.0 with a 95% credible interval of 1.6 to 2.6. 11/18
Having two very different methods give Rt estimates of between 2.0 and 2.5 gives me some (small) degree of confidence. We can triangulate relative fitness with Rt so that Delta in South Africa is at Rt of ~0.8 and Omicron is at about three times this with Rt of ~2.5. 12/18
We can then use the approach here to factor possible scenarios of intrinsic transmission vs immune escape that would give Omicron Rt of 2.5. 13/18
Under a scenario of 90% population immunity against previous variants, we get the following picture where Omicron could lie anywhere along the dashed line ranging from an intrinsic R0 of 3 and 83% immune escape to an intrinsic R0 of 9 and 20% immune escape. 14/18
Note the these estimates are sensitive to assumed population immunity. Under a scenario of 85% population immunity, we get the following picture instead that shifts the required level of immune escape upwards for a particular R0 value. 15/18
Again, based on wildly divergent spike protein, I'm guessing that immune escape will be substantial and so I still suspect that it's quite possible that Omicron will show lower intrinsic transmissibility than Delta. My updated diagram. 16/18
Note also that high immune escape, lower intrinsic transmissibility is not necessarily a good thing. Higher immune escape places previously infected and vaccinated individuals more at risk. 17/18
We'll know much more about this level of risk in ~2 weeks when we get neutralization results. I'm particularly interested in neutralization titers of individuals with two doses of vaccine vs individuals with three doses of vaccine. 18/18
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Currently, the US is reporting about 54k daily cases of COVID-19 (16 per 100k per capita) and the UK is reporting about 4k (6 per 100k). This seems comfortingly low compared to even this summer's BA.5 wave and let alone last winter's BA.1 wave. Figure from @OurWorldInData. 1/16
However, at this point, nearly all infections will be in individuals with prior immunity from vaccination or infection and this combined with a roll back in testing makes it unclear how to interpret current case counts compared to previous time periods. 2/16
We're interested in the case detection rate or the ratio of underlying new infections compared to reported cases. Throughout much of 2020 and 2021, I had a working estimate of 1 infection in ~3.5 getting reported as a case. 3/16
Largely through partial immune escape, lineage BA.5 viruses resulted in sizable epidemics throughout much of the world. However, in most countries these epidemics are now beginning to wind down. What do we expect after BA.5? 1/10
Lineage BA.2.75 (aka 'Centaurus') has been high on watch lists due to sustained increase in frequency in India combined with the presence of multiple mutations to spike protein. We now have enough sampled BA.2.75 viruses from outside India to make some initial conclusions. 2/10
If we look at frequency data we see sustained logistic growth of BA.2.75 in India, Japan, Singapore and the US. Critically, in India it is clearly displacing BA.5. 3/10
Based on the experience in winter 2020/2021, seasonal influence on SARS-CoV-2 transmission is quite clear, but much of the Northern Hemisphere is currently experiencing large summer epidemics driven the spread of evolved BA.5 viruses. 1/11
It's necessarily fraught to try to make predictions of seasonal circulation patterns going forwards, but we can gain some intuition from simple epidemiological models. 2/11
In particular, we can use an SIRS system in which individuals go from Susceptible to Infected to Recovered, and then return to the Susceptible class due to immune waning / antigenic drift of the virus. 3/11
There seems to be a worry that telling people we've exited the "pandemic phase" will lead to further reduced precautions. As always however, I think it's best not to conduct messaging for intended behavioral effect and just try to make scientifically accurate statements. 1/5
Given vaccination and infection, the US and global population now has widespread immunity to SARS-CoV-2 and deaths per-infection are about 10 times lower than they were pre-immunity in 2020 with a ballpark IFR of 0.05% (though this will vary by immunity and age demographics). 2/5
You can see this reduction in mortality rate in looking at projections of deaths from lagged-cases keyed to early case fatality rate. 3/5
The @US_FDA VRBPAC committee will be meeting tomorrow to discuss variant-specific COVID-19 vaccines (fda.gov/advisory-commi…). Based on present observations, I would argue that the most important metric to optimize are titers against BA.4/BA.5 viruses. 1/10
We've seen repeated replacement of SARS-CoV-2 variants during 2022, first of Delta by Omicron BA.1 and then by sub-lineages of Omicron, with BA.2 replacing BA.1 and now with BA.4/BA.5 replacing BA.2. 2/10
Viruses have been evolving to be higher fitness through both increases in intrinsic transmissibility (seen in BA.2 vs BA.1) as well as escape from existing population immunity (seen in Omicron vs Delta as well as BA.4/BA.5 vs BA.2). 3/10
Global monkeypox confirmed and suspected cases compiled by @globaldothealth show initial rapid increase as case-based surveillance comes online, followed by slower continued growth. 1/10
This is data from github.com/globaldothealt… and has had a 7-day smoothing applied and all y-axes are shown on a log scale. 2/10
If we focus on the last 11 days, we can see steady exponential growth in global cases with a ~7.7 day doubling. 3/10